This article is more than 5 years old. Information may no longer be current.
VIDEO: James M. McKenney, PharmD, discusses strategies for LDL reduction
Click Here to Manage Email Alerts
CHICAGO — In this video, James M. McKenney, PharmD, president and CEO of National Clinical Research, offers highlights emerging lipid-modifying therapies for patients with cholesterol disorders.
In particular, he discussed PCSK9 monoclonal antibodies, which produced an additional 60% reduction to LDL when added to statin therapy in clinical trials. McKenney said that the PCSK9 inhibitors are going to be "wonderful therapies" that, if approved, will allow for certain patients to achieve LDL goals for the first time, including those with familial hypercholesterolemia and who are intolerant to statins.
McKenney also addressed two new CETP inhibitors that are currently under clinical investigation, with results anticipated next year. McKenney said there is "reason to believe" the results from these trials may be positive, and that the drugs have been shown to not only lower LDL but also raise HDL.